Biogen/$BIIB
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Biogen
Biogen is an established biopharmaceutical company focused on treatments for neurological diseases and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 45% of total revenue in 2024. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (18% of total in 2024), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
Ticker
$BIIB
Sector
Primary listing
Employees
7,605
Headquarters
Website
Biogen Metrics
BasicAdvanced
$26B
15.86
$10.97
0.14
-
Price and volume
Market cap
$26B
Beta
0.14
52-week high
$185.17
52-week low
$110.04
Average daily volume
1.9M
Financial strength
Current ratio
2.716
Quick ratio
1.766
Long term debt to equity
36.194
Total debt to equity
36.194
Interest coverage (TTM)
10.18%
Profitability
EBITDA (TTM)
3,409.3
Gross margin (TTM)
76.56%
Net profit margin (TTM)
15.98%
Operating margin (TTM)
26.28%
Effective tax rate (TTM)
15.52%
Revenue per employee (TTM)
$1,320,000
Management effectiveness
Return on assets (TTM)
5.75%
Return on equity (TTM)
9.31%
Valuation
Price to earnings (TTM)
15.864
Price to revenue (TTM)
2.53
Price to book
1.4
Price to tangible book (TTM)
10.71
Price to free cash flow (TTM)
11.258
Free cash flow yield (TTM)
8.88%
Free cash flow per share (TTM)
15.465
Growth
Revenue change (TTM)
4.77%
Earnings per share change (TTM)
-0.78%
3-year revenue growth (CAGR)
-0.97%
10-year revenue growth (CAGR)
-0.48%
3-year earnings per share growth (CAGR)
-17.50%
10-year earnings per share growth (CAGR)
-3.27%
What the Analysts think about Biogen
Analyst ratings (Buy, Hold, Sell) for Biogen stock.
Biogen Financial Performance
Revenues and expenses
Biogen Earnings Performance
Company profitability
Biogen News
AllArticlesVideos
Biogen Receives Health Canada Authorization for ZURZUVAE™ (zuranolone), the First and Only Treatment Indicated for Adults with Postpartum Depression in Canada
Business Wire·6 days ago
Stoke Therapeutics and Biogen Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting
Business Wire·1 week ago
Stoke Therapeutics and Biogen Announce Presentations at the 2025 American Epilepsy Society Annual Meeting
Business Wire·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Biogen stock?
Biogen (BIIB) has a market cap of $26B as of December 15, 2025.
What is the P/E ratio for Biogen stock?
The price to earnings (P/E) ratio for Biogen (BIIB) stock is 15.86 as of December 15, 2025.
Does Biogen stock pay dividends?
No, Biogen (BIIB) stock does not pay dividends to its shareholders as of December 15, 2025.
When is the next Biogen dividend payment date?
Biogen (BIIB) stock does not pay dividends to its shareholders.
What is the beta indicator for Biogen?
Biogen (BIIB) has a beta rating of 0.14. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.